For example, SM08502 (Cirtuvivint), the first small‐molecule CLK inhibitor to enter clinical trials, inhibits multiple kinases, such as MAP4K4, MINK1, and LRRK2.[31] Research suggests that LRRK2 inhibition could lead to the development of intestinal‐immune diseases.[32] Previous studies have shown that targeting Msn kinases (MINK1 and MAP4K4) can promote regenerative proliferation.[33] ML315, another potent CLK4 inhibitor with an IC50 value of 68 nm, inhibits CLK1 (68 nm) and CLK2 (231 nm). The gene discussed is LRRK2; the disease is immune system disorder.